Lantern Pharma
Curated by SignalDeveloping drug and companion diagnostics for multi-drug resistant cancers
Overview
Developing drug and companion diagnostics for multi-drug resistant cancers. Its approach is to biomarker-biased genetic screening to identify and treat patients that would benefit most from our drugs. Its lead candidate is Irovfulven-1, a new class of anti-tumor agents to treat multi-drug-resistant cancers.
Key facts
- Founded
- 2013
- Headquarters
- Dallas, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 3 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view
- Phone
- Sign up to view
Open roles
4 rolesPrecision Oncology Clinical Trial Coordinator
Plano, TX · On-site · Volunteer
Bio-Curation Scientist
Bengaluru, Karnataka, India · On-site · Volunteer
Bio-Curator / Biocuration Scientist
Bengaluru, Karnataka, India · On-site · Temporary